100949-89-1

Basic information

• Product Name: 4-methyl-2-(4-methylpiperazin-1-yl)quinoline
• Synonyms: 4-methyl-2-(4-methylpiperazin-1-yl)quinoline
• CAS NO: 100949-89-1
• Molecular Weight: 241.336
• Mol File: 100949-89-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-methyl-2-(4-methylpiperazin-1-yl)quinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-2-(4-methylpiperazin-1-yl)quinoline(100949-89-1)
• EPA Substance Registry System: 4-methyl-2-(4-methylpiperazin-1-yl)quinoline(100949-89-1)

Safety Data

• Hazardous Substances Data: 100949-89-1(Hazardous Substances Data)

Usage

Description

4-Methyl-2-(4-methylpiperazin-1-yl)quinoline is an organic compound characterized by its quinoline core structure, featuring a methyl group at the 4th position and a 4-methylpiperazin-1-yl group at the 2nd position. 4-methyl-2-(4-methylpiperazin-1-yl)quinoline is known for its potential applications in various fields due to its unique chemical properties and structural features.

Uses

Used in Pharmaceutical Industry:
4-Methyl-2-(4-methylpiperazin-1-yl)quinoline is used as a reactant in the preparation of an antagonist that selectively modulates native TRPC4/C5 ion channels. This application is significant because the modulation of these ion channels can have therapeutic effects on various conditions, such as hypertension, chronic pain, and certain neurological disorders. By acting as a reactant in the synthesis of such antagonists, 4-methyl-2-(4-methylpiperazin-1-yl)quinoline plays a crucial role in the development of novel pharmaceuticals targeting TRPC4/C5 ion channels.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 634-47-9 2-chloro-4-methylquinoline 

Relevant articles and documents

6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode

Novel 6-acylamino-2-aminoquinoline melanin-concentrating hormone 1 receptor (MCH1R) antagonists were identified by sequential in silico screening with 3D pharmacophore models derived from a series of benzamide antagonists. The structure-activity relationship exploration by synthesis of analogues found structural demands around the western part of the compounds to be quite specific, whereas much structural freedom was found in the eastern part. While these compounds in general suffered from poor solubility properties, the 4-trifluoromethoxy-phenoxyacetamide western appendage provided a favorable combination of activity and solubility properties. The amine in the eastern appendage, originally required by the pharmacophore model and believed to interact with Asp123 in transmembrane 3 of MCH1R, could be removed without diminishing affinity or functional activity of the compounds. Docking studies suggested that the Asp123 interacts preferentially with the nitrogen of the central quinoline. Synthesis and testing of specific analogues supported our revised binding mode hypothesis.

Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists

A new series of 2-aminoquinolines has been identified as antagonists of the melanin concentrating hormone receptor (MCH-1R). Syntheses and structure-activity relationships are described leading to a compound having low nanomolar activity against the receptor and demonstrating functional antagonism. Studies also showed that some of the compounds were selective against a range of other G protein-coupled receptors.